Cargando…
Should We Use Renin-Angiotensin-Aldosterone System Inhibitors Routinely in Patients With Hypertrophic Cardiomyopathy?
Autor principal: | Park, Jae-Hyeong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Cardiology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475692/ https://www.ncbi.nlm.nih.gov/pubmed/37653697 http://dx.doi.org/10.4070/kcj.2023.0161 |
Ejemplares similares
-
Should we continue to use renin–angiotensin–aldosterone system blockers in patients with COVID-19?
por: Copur, Sidar, et al.
Publicado: (2022) -
Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19
por: Jarcho, John A., et al.
Publicado: (2020) -
Renin-angiotensin-aldosterone system inhibitors and the COVID-19 epidemic
por: Silva-Cardoso, José, et al.
Publicado: (2022) -
Intradialytic hypotension and cardiac remodeling: should we consider the renin-angiotensin-aldosterone system?
por: Wang, Juanli, et al.
Publicado: (2021) -
Role of the Renin–Angiotensin–Aldosterone System in Dystrophin-Deficient Cardiomyopathy
por: Rodriguez-Gonzalez, Moises, et al.
Publicado: (2020)